Oryzon Genomics is a clinical stage biopharmaceutical company that discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. The Company has a technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon’s strategy is to develop compounds against novel epigenetic targets through Phase II clinical trials.